Hovione offers the opportunity for early partnering under flexible collaboration structures such as Licensing, Investment and Co-development business models.
Hovione has a diversified portfolio of proprietary products currently under development, comprising known APIs which have been formulated (505b2/hybrid), in the areas of dermatology, ophthalmology, and respiratory. Hovione is pursuing partnerships for its assets which can take the form of licensing arrangements, investment opportunities, or co-development collaborations.
Hovione’s primary objective is to advance the development of our pipeline by working with partners that share our desire to provide patients with solutions to unmet clinical needs. We’re happy to discuss a variety of business models with interested companies. Please contact us today!
Areas of Collaboration
Hovione’s portfolio mirrors its technical expertise and knowledge in chemistry and particle engineering. Our drug product pipeline is strategically connected to the utilization of these core competencies in areas such as:
- Identification and process development of patent protected new salt forms and polymorphs;
- Dry powder inhalation formulation and device design
- Drug repositioning by altering delivery to a new route of administration
- Achieving tight particle specifications for targeted delivery and release
Approach to Co-Development
Hovione seeks co-development partnerships with development/manufacturing organizations which have synergistic technologies to jointly advance drug product development. We are interested in speaking with companies that share our vision in dermatology, ophthalmology, and respiratory.
If you want to learn more about partnering opportunities please contact our team.